Skip to main content
Indices

Endpoint Index

A simple equal-weight index of active Endpoint Arena markets. It updates with live YES prices, so you can quickly see whether the market is getting more or less confident about upcoming trial readouts.

Index Tape

Index Level
53.1%
0%50%100%
Active Markets
16
Move From Open
-1.1 pts
Range
41%-65%

Index History

Latest
53.1%
Since Start
-4.8 pts
Markets
16
62%54%46%Aug 12Oct 6

Market Mix

Clinical Sleeves
Oncology6 markets
Trend
Avg YES48.4%
Move+0.4 pts
Weight37.5%
Other5 markets
Trend
Avg YES54.2%
Move-4.8 pts
Weight31.3%
CNS2 markets
Trend
Avg YES56.4%
Move-0.1 pts
Weight12.5%
Cardio/Renal1 market
Trend
Avg YES43.2%
Move+1.2 pts
Weight6.3%
Infectious Disease1 market
Trend
Avg YES70.4%
Move+2.4 pts
Weight6.3%
Metabolic1 market
Trend
Avg YES62.0%
Move0.0 pts
Weight6.3%
Phase Sleeves
Phase 316 markets
Trend
Avg YES53.1%
Move-1.1 pts
Weight100.0%

Constituents

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Ticker
PFE
Drug Market
—
Readout
12/30/26
Sleeve
Oncology
Phase
Phase 3
YES
37.2%
Move
-1.8
Weight
6.3%
KarXT for Alzheimer’s psychosis (ADEPT-4)
Ticker
BMY
Drug Market
—
Readout
12/31/26
Sleeve
CNS
Phase
Phase 3
YES
44.5%
Move
-7.5
Weight
6.3%
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Ticker
INCY
Drug Market
—
Readout
12/31/26
Sleeve
Other
Phase
Phase 3
YES
29.9%
Move
-24.1
Weight
6.3%
Sacituzumab tirumotecan for lung cancer (TroFuse-004)
Ticker
MRK
Drug Market
—
Readout
05/31/27
Sleeve
Oncology
Phase
Phase 3
YES
46.0%
Move
0.0
Weight
6.3%
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Ticker
AURA
Drug Market
—
Readout
11/15/27
Sleeve
Oncology
Phase
Phase 3
YES
58.0%
Move
+8.0
Weight
6.3%
Balcinrenone/dapagliflozin for heart failure (BalanceD-HF)
Ticker
AZN
Drug Market
—
Readout
12/31/27
Sleeve
Cardio/Renal
Phase
Phase 3
YES
43.2%
Move
+1.2
Weight
6.3%
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Ticker
SNY
Drug Market
—
Readout
12/31/27
Sleeve
CNS
Phase
Phase 3
YES
68.2%
Move
+7.2
Weight
6.3%
Fianlimab/cemiplimab for melanoma (HARMONY)
Ticker
REGN
Drug Market
—
Readout
12/31/27
Sleeve
Oncology
Phase
Phase 3
YES
48.5%
Move
+1.5
Weight
6.3%
Inavolisib for HER2-positive breast cancer (INAVO122)
Ticker
RHHBY
Drug Market
—
Readout
12/31/27
Sleeve
Oncology
Phase
Phase 3
YES
55.2%
Move
-4.8
Weight
6.3%
Milvexian for atrial fibrillation (LIBREXIA-AF)
Ticker
JNJ
Drug Market
—
Readout
12/31/27
Sleeve
Other
Phase
Phase 3
YES
44.9%
Move
-1.1
Weight
6.3%
Retatrutide vs tirzepatide for obesity (TRIUMPH-5)
Ticker
LLY
Drug Market
—
Readout
12/31/27
Sleeve
Metabolic
Phase
Phase 3
YES
62.0%
Move
0.0
Weight
6.3%
Ruxolitinib cream for childhood vitiligo
Ticker
INCY
Drug Market
—
Readout
12/31/27
Sleeve
Other
Phase
Phase 3
YES
73.0%
Move
+1.0
Weight
6.3%
Tenapanor for chronic constipation (ACCEL)
Ticker
ARDX
Drug Market
—
Readout
12/31/27
Sleeve
Other
Phase
Phase 3
YES
62.3%
Move
+0.3
Weight
6.3%
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ticker
AMGN
Drug Market
—
Readout
02/29/28
Sleeve
Oncology
Phase
Phase 3
YES
45.8%
Move
-0.2
Weight
6.3%
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Ticker
MRK
Drug Market
—
Readout
09/30/28
Sleeve
Infectious Disease
Phase
Phase 3
YES
70.4%
Move
+2.4
Weight
6.3%
Felzartamab for IgA nephropathy
Ticker
BIIB
Drug Market
—
Readout
12/31/29
Sleeve
Other
Phase
Phase 3
YES
61.0%
Move
0.0
Weight
6.3%